A prospective cohort study on the relationship between vancomycin steady-state trough concentration and efficacy and safety in Chinese adults

doi:10.5246/jcps.2020.05.032

Abstract

Abstract:

Clinical guidelines recommend a steady-state vancomycin(VCM) trough concentration (SVTC) of 10–15 mg/L for regular infections and 15–20 mg/L for severe infections. However, clinical trials have shown that increasing SVTC is not beneficial for efficacy, and instead it leads to nephrotoxicity. To verify whether increasing the SVTC results in improved clinical outcomes with sustainable adverse effects, we prospectively determined its correlation with clinical efficacy and safety. The participants included patients hospitalized with Gram-positive bacterial infections from March 2017 through October 2018. The patients were classified into group I (SVTC<10 mg/L), II (10≤SVTC≤20 mg/L), or III (SVTC>20 mg/L). Clinical, microbiological, and laboratory data were collected. Clinical outcomes between group I and IIwere matched after propensity score matching (PSM). A total of 331 patients were included in this study. Clinical failure occurred in 59 (29%) of 204 patients on day 14, with no significant differencebetween groups I and II (P = 0.535). Infection recurred at 28 d in 62 (30%) of 204 patients, and no significant difference ininfection recurrence was observed between both the groups (log-rank, P = 0.674). Except for a significant increase in the incidence of acute kidney injury in group II, no significant difference was observed between two groups for any clinical results. The incidence of adverse events in groups I and II was significantly lower than that in group III (P<0.001). SVTC had an applicable cut-off point at 14.55 mg/L. SVTC was not correlated with VCMclinical efficacy, while it was a good indicator of nephrotoxicity.

Key words: Vancomycin, Therapeutic drug monitoring, Nephrotoxicity, Propensity score matching

CLC Number:

Supporting:

Chaohui Wu, Huifen Lin, Weiwei Lin, Yiwei Liu, Xiang You, Cuihong Lin, Rongfang Lin, Dayong Zeng, Pinfang Huang. A prospective cohort study on the relationship between vancomycin steady-state trough concentration and efficacy and safety in Chinese adults[J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(5): 341-354.

References

[1] Mark, P.; Wilhelm, M.D. Vancomycin. Div. Infect. Dis. Int. Med. 1991, 66, 1165-1170.

[2] Moellering, R.C. Jr. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 2006, 42 Suppl 1, S3-S4.

[3] Lodise, T.P.; Drusano, G.L.; Zasowski, E.; Dihmess, A.; Lazariu, V.; Cosler, L.; McNutt, L.A. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin. Infect. Dis. 2014, 59, 666-675.

[4] Heil, E.L.; Claeys, K.C.; Mynatt, R.P.; Hopkins, T.L.; Brade, K.; Watt, I.; Rybak, M.J.; Pogue, J.M. Making the change to area under the curve-based vancomycin dosing. Am. J. Health Syst. Pharm. 2018, 75, 1986-1995.

[5] Drennan, P.G.; Begg, E.J.; Gardiner, S.J.; Kirkpatrick, C.M.J.; Chambers, S.T. The dosing and monitoring of vancomycin: what is the best way forward? Int. J. Antimicrob. Agents. 2019, 53, 401-407.

[6] Rybak, M.; Lomaestro, B.; Rotschafer, J.C.; Moellering, R. Jr, Craig, W.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am. J. Health Syst. Pharm. 2009, 66, 82-98.

[7] Chen, B.Y; Guan, X.D.; He, L.X.; Hu, J.; Huang, J.Y.; Li, G.H.; Lu, Q.; Ni, L.Q.; Ni, Y.X.; Shan, A.L.; Shen, H.H.; Shen, Z.X.; Shi, Y.; Wang, C.H.; Wang, R.; Wen, F.Q.; Wen, X.H.; Xiao, Y.H.; Xie, C.M.; Xu, Y.C.; Yang, Y.; Yu, Y.S.; Zhang, J; Zhang, W.H.; Zhang, X.Z.; Zhou, J.X.; Zhou, L.F. Chinese expert consensus on the clinical application of vancomycin. Chin. J. New Drugs Clin. Med. 2011, 30, 561-573.

[8] Liu, C.; Bayer, A.; Cosgrove, S.E.; Daum, R.S.; Fridkin, S.K.; Gorwitz, R.J.; Kaplan, S.L.; Karchmer, A.W.; Levine, D.P.; Murray, B.E.; J Rybak, M.; Talan, D.A.; Chambers, H.F. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 2011, 52, 285-292.

[9] Matsumoto, K.; Takesue, Y.; Ohmagari, N.; Mochizuki, T.; Mikamo, H.; Seki, M.; Takakura, S.; Tokimatsu, I.; Takahashi, Y.; Kasahara, K.; Okada, K.; Igarashi, M.; Kobayashi, M.; Hamada, Y.; Kimura, M.; Nishi, Y.; Tanigawara, Y.; Kimura, T. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J. Infect. Chemother. 2013, 19, 365-380.

[10] Patel, N.; Pai, M.P.; Rodvold, K.A.; Lomaestro, B.; Drusano, G.L.; Lodise, T.P. Vancomycin: we can’t get there from Here. Clin. Infect. Dis. 2011, 52, 969-974.

[11] Ye, Z.K.; Chen, Y.L.; Chen, K.; Zhang, X.L.; Du, G.H.; He, B.; Li, D.K.; Liu, Y.N.; Yang, K.H.; Zhang, Y.Y.; Zhai, S.D.; Guideline Steering Group, the Guideline Development Group and the Guideline Secretary Group. Therapeutic drug monitoring of vancomycin: a guideline of the Division of therapeutic drug monitoring, Chinese pharmacological society. J. Antimicrob. Chemother. 2016, 71, 3020-3025.

[12] Zhang, H.L.; Wen, Y.; Tan, S.Y.; Liu, T.T. Evidence-based medicine for trough serum concentration of vancomycin in Chinese adults. Chin. J. Biochem. Drugs. 2015, 35, 107-115.

[13] Cao, G.; Liang, X.; Zhang, J.; Zhou, Y.; Wu, J.; Zhang, Y.; Chen, Y.; Huang, J.; Liu, X.; Yu, J. Vancomycin serum trough concentration vs. clinical outcome in patients with gram-positive infection: a retrospective analysis. J. Clin. Pharm. Ther. 2015, 40, 640-644.

[14] Liang, X.Y.; Fan, Y.X.; Yang, M.J.; Zhang, J.; Wu, J.F.; Yu, J.C.; Tao, J.H.; Lu, G.P.; Zhang, H.F.; Wang, R.L.; Wen, X.X.; Li, H.Y.; Zhang, F.Y.; Hang, J.Q.; Shen, L.H.; Zhang, Z.W.; Lin, Q.H.; Fu, F.M.; Wu, S.B.; Shen, B.; Huang, W.F.; Chang, C.K.; Zhang, H.; Huang, Q.W.; Shi, Y.F.; Ren, H.; Yuan, Q.; Song, X.L.; Luo, X.M.; Zhang, H. A prospective multicenter clinical observational study on vancomycin efficiency and safety with therapeutic drug monitoring. Clin. Infect. Dis. 2018, 67, S249-S255.

[15] Zhang, H.F.; Wang, R.L.; Shu, W.; Tang, R.; Liang, X.Y.; Zhang, J.; Wu, J.F. Monitoring of vancomycin serum concentrations and the evaluation of its safety and treatment outcomes in adult patients. Chin. Crit. Care Med. 2018, 30, 538-543.

[16] Food and Drug Administration. Guideline for evaluating clinical studies of antimicrobials in the division of anti-infective drug products. 1997, 02-18.

[17] Bone, R.C.; Balk, R.A.; Cerra, F.B. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for Sepsis and organ failure and guidelines for the use of innovative therapies in Sepsis. Crit. Care Med. 1992, 20, 864-874.

[18] Horan, T.C.; Andrus, M.; Dudeck, M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am. J. Infect. Control. 2008, 36, 309-332.

[19] Bellomo, R.; Kellum, J.A.; Ronco, C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med. 2007, 33, 409-413.

[20] Finch, N.A.; Zasowski, E.J.; Murray, K.P.; Mynatt, R.P.; Zhao, J.J.; Yost, R.; Pogue, J.M.; Rybak, M.J. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob. Agents Chemother. 2017, 61, e01293-e01217.

[21] Rybak, M.J. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 2006, 42 Suppl 1, S35-S39.

[22] Neely, M.N.; Youn, G.; Jones, B.; Jelliffe, R.W.; Drusano, G.L.; Rodvold, K.A.; Lodise, T.P. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob. Agents Chemother. 2014, 58, 309-316.

[23] Neely, M.N.; Kato, L.; Youn, G.; Kraler, L.; Bayard, D.; van Guilder, M.; Schumitzky, A.; Yamada, W.; Jones, B.; Minejima, E. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob. Agents Chemother. 2018, 62, e02042-e02017.

[24] Álvarez, R.; López Cortés, L.E.; Molina, J.; Cisneros, J.M.; Pachón, J. Optimizing the clinical use of vancomycin. Antimicrob. Agents Chemother. 2016, 60, 2601-2609.

[25] Hale, C.M.; Seabury, R.W.; Steele, J.M.; Darko, W.; Miller, C.D. Are vancomycin trough concentrations of 15 to 20 mg/L associated with increased attainment of an AUC/MIC ≥ 400 in patients with presumed MRSA infection? J. Pharm. Pract. 2017, 30, 329-335.

[26] Zhang, J.L.; Zhou, J.; Chen, J.H.; Chen, T.; Liu, Y.; Tian, H.P.; Zhang, J. Analysis for the vancomycin plasma concentration data in infants by clinical pharmacists. J. Chin. Pharm. Sci. 2015, 24, 263-266.

[27] Zhou, J.; Zhu, Y.; Zhang, M. A reference for clinical practice of vancomycin according to pharmacokinetic modelling based on plasma concentration monitoring in children. Clin. PediatrEmerg. Med. 2015, 22, 383-6.

[28] Jung, Y.; Song, K.H.; Cho, J.e.; Kim, H.S.; Kim, N.H.; Kim, T.S.; Choe, P.G.; Chung, J.Y.; Park, W.B.; Bang, J.H.; Kim, E.S.; Park, K.U.; Park, S.W.; Kim, H.B.; Kim, N.J.; Oh, M.D. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int. J. Antimicrob. Agents. 2014, 43, 179-183.

[29] Martirosov, D.M.; Bidell, M.R.; Pai, M.P.; Scheetz, M.H.; Rosenkranz, S.L.; Lodise, T.P. Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5mg/L: a pilot study. Diagn. Microbiol. Infect. Dis. 2017, 88, 259-263.

[30] San-Juan, R.; Fernández-Ruiz, M.; Gasch, O.; Camoez, M.; López-Medrano, F.; Domínguez, M.Á.; Almirante, B.; Padilla, B.; Pujol, M.; Aguado, J.M.; REIPI/GEIH Study Group. High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 2017, 72, 2102-2109.

[31] Jacob, J.T.; DiazGranados, C.A. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int. J. Infect. Dis. 2013, 17, e93-e100.

[32] Bosso, J.A.; Nappi, J.; Rudisill, C.; Wellein, M.; Bookstaver, P.B.; Swindler, J.; Mauldin, P.D. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob. Agents Chemother. 2011, 55, 5475-5479.

[33] Jeffres, M.N. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017, 77, 1143-1154.

[34] Minejima, E.; Choi, J.; Beringer, P.; Lou, M.M.; Tse, E.; Wong-Beringer, A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob. Agents Chemother. 2011, 55, 3278-3283.

[35] Meaney, C.J.; Hynicka, L.M.; Tsoukleris, M.G. Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. Pharmacotherapy. 2014, 34, 653-661.

[36] Contreiras, C.; Legal, M.; Lau, T.T.; Thalakada, R.; Shalansky, S.; Ensom, M.H. Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy. Can. J. Hosp. Pharm. 2014, 67, 126-132.

[37] Jeffres, M.N.; Isakow, W.; Doherty, J.A.; Micek, S.T.; Kollef, M.H. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther. 2007, 29, 1107-1115.